The COVID-19 Pandemic – Products

Because RSV, influenza, and COVID-19 share symptoms, accurate testing is needed to distinguish one from the other. The CE-IVD marked multiplex TaqPath COVID-19, Flu A/B, RSV Combo Kit is specifically designed to detect and differentiate between these three viruses during flu season

Partnership between two Canadian life sciences leaders offers a commercial GMP manufacturing solution for Acuitas’ licensed partners developing promising next generation therapies.

The National Institutes of Health selected Exothera S.A. therapeutics to develop the manufacturing process for NIH’s intranasal vaccine against SARS-CoV-2.

While the industry was put front and center during the COVID-19 pandemic, diagnostics have always been critical in treating illnesses and managing health. Technological advances, innovative platforms, and decentralized test options are driving exciting developments and optimism across the diagnostics industry.

A team of scientists led by the University of Oxford have achieved a significant breakthrough in detecting modifications on protein structures.

New ready-to-ship xGen™ NGS solution will enable researchers to combat challenging diseases of today and prepare for the next pathogen of tomorrow.

PrecisionLife, has announced the results of its long COVID study, providing the first detailed genetic insights into the condition and its commonalities with other diseases, including myalgic encephalomyelitis/chronic fatigue syndrome.

The Center for Emerging Viral Threats (CEVT) in Louisiana, USA, is using INTEGRA Biosciences’ liquid handling solutions for COVID-19 testing and viral genomics studies.

Meissa Vaccines announced it has entered into a manufacturing agreement with Exothera S.A. delivering customized process development and GMP manufacturing services for vaccines, viral vectors and nucleic acids.

Honeycomb Biotechnologies and Revvity have announced the launch of a suite of new solutions and services that expand the frontiers of single-cell biology.